QUOTE AND NEWS
FiercePharma  Jun 28  Comment 
Two former Ariad employees and one spouse of a former employee are in hot water for alleged insider trading surrounding the company’s safety problems with Iclusig back in 2013.
GenEng News  Jun 28  Comment 
Two former senior employees, and the husband of a third former employee, of Ariad Pharmaceuticals —acquired earlier this year by Takeda Pharma—have been charged with illegal insider trading related to selloffs of the company’s stock in...
MarketWatch  Jun 27  Comment 
The Securities and Exchange Commission brought insider trading charges on Tuesday against two former senior employees and the spouse of a former employee of Ariad Pharmaceuticals, Inc.[s:Aria] for allegedly trading in advance of announcements...
FierceBiotech  Jun 8  Comment 
Following a major reorganization earlier this year that saw it sell off its marketed med and revert back to being a clinical-stage biotech, Merrimack is making major changes in its executive team, announcing today that former Ariad chief medical...
FiercePharma  May 5  Comment 
FiercePharmaAsia—Takeda’s Ariad reward, WuXi NextCODE’s Series B, Dr. Reddy’s new FDA slap aliu Fri, 05/05/2017 - 08:38
FiercePharma  Apr 28  Comment 
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig esagonowsky Fri, 04/28/2017 - 13:54
FiercePharma  Apr 7  Comment 
FiercePharmaAsia—Gilead’s manufacturing site in China, Takeda’s IBD deal and 180 Ariad job cuts aliu Fri, 04/07/2017 - 09:38
GenEng News  Mar 30  Comment 
Takeda Pharmaceutical has absorbed only part of the nearly 300-employee workforce it inherited when it acquired Ariad Pharmaceuticals earlier this year, though exactly how many of the staffers it will ultimately hire has yet to be determined. ...
Motley Fool  Feb 6  Comment 
The drugmaker's stock soared last month on a rich buyout offer from Japan's Takeda Pharmaceutical.




 

Ariad Pharmaceuticals develops products that use intracellular-signal-transduction pathways to treat disease. It is developing pharmaceuticals that may treat conditions such as anemia, growth-hormone deficiency, cancer, diabetes, asthma, arthritis, and osteoporosis. All of the company's products are in the research or clinical-testing stages. Ariad has not entered any partnerships for the distribution of their product candidates, preferring to have sole control of their development.





References

Morningstar.com

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki